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Abstract
            Implantable Cardioverter Defibrillator (ICD) implantation is the only established therapy 
for primary or secondary prevention of sudden cardiac death in patients with Hypertrophic 
Cardiomyopathy (HCM). Ineffectiveness of shock therapy for the termination of potentially fatal 
ventricular arrhythmias in ICD recipients is rare in the presence of appropriate arrhythmia 
detection by the device. We report the case of a 48-year-old woman with HCM and a single 
chamber ICD, who received five inefficient high-energy (35 Joules) shocks for the termination 
of an appropriately detected episode of Ventricular Tachycardia (VT). The episode was safely 
terminated with a subsequent application of Antitachycardia Pacing (ATP) by the device. At the 
following ICD control, an acceptable defibrillation threshold was detected.
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Introduction
            Implantable Cardioverter-Defibrillators (ICDs) can  terminate  ventricular  tachycardias 
(VTs)   painlessly   with   antitachycardia   pacing   (ATP),   especially               in   episodes   of 
spontaneous VT with cycle length (CL) >300 ms1-3, while concerns   exist about efficacy and  
safety of ATP in VT episodes with shorter CL (Fast VT, FVT)2,3. High-energy intracardiac 
shocks are almost always  effective for the termination of VTs in the absence of ICD 
dysfunction4.  
            We report a case of efficient ATP therapy for the termination of a FVT episode after five 
inefficient high-energy (35 Joules) intracardiac shocks in an ICD recipient with Hypertrophic 
Cardiomyopathy (HCM). The post-episode ICD control revealed  normal functional parameters 
of the device and acceptable defibrillation threshold test.                                      
Case
            An 48-year-old female ICD recipient was admitted to our institution due to an episode of 
tachycardia, which was detected as VT and was followed by five consecutive   ineffective 
discharges of the device. The patient had a history of Hypertrophic-Obstructive Cardiomyopathy 
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(HOCM) with transcoronary ablation of septal hypertrophy (TASH) 7 years ago and was 
receiving 240 mg of Verapamil daily. A single-chamber   (VVI)   ICD was implanted to the 
patient one year ago for secondary prevention after an episode of spontaneous sustained VT. 
[Single Chamber-ICD Medtronic™ Model: Maximo VR 7232, Singlecoil electrode 6931 
Medtronic™; Parameter: VT 330ms (Therapy: Rx1: 3 sequences Burst 5 Impulses R-S1 
Intervall 84%; Rx2: 3 sequences Ramp 5 Impulses R-S1 Interval 81%: Rx 3-6: cardioversion 
35J), FVT 250ms (Therapy: Rx1: 1 sequence Burst 5 Impulses R-S1 Interval 88%: Rx 2-6: 
cardioversion), VF 280ms (Therapy 6 times DC-Shock 35J). SVT discrimination: Stability 
30ms, Onset: 81%. Stimulation parameter: VVI 60 bpm]. On transthoracic echocardiographic 
examination, the left ventricular systolic function was normal with  no detectable intraventricular 
gradient,   while   routine   laboratory   blood   tests   showed   normal   findings.
               A few days before admission, the patient was abruptly awaked   by consecutive 
discharges of the ICD. The following ICD control revealed an episode of an almost regular 
tachycardia with cycle length 330 to 270ms (spontaneously accelerated tachycardia), interpreted 
by the ICD as VT. The subsequent intervention of the device started with one ineffective ATP 
burst which was followed by five maximum-energy shocks (35 Joules), which were also 
ineffective. Finally, the tachycardia was successfully terminated  after  the application of a new 
ATP burst (Figure 1).
            The rest findings of the ICD control regarding the functional  parameters of the can  and 
electrode were normal and the defibrillation threshold test was also acceptable, below 17 Joules 
(Figure 2). The patient's rest ECG revealed atrial fibrillation (of unknown onset) and pacing 
ventricular rhythm. Coronary angiography was performed showing normal coronary arteries, 
while left ventriculography confirmed the echocardiographic findings. 
            Regarding that the unusual outcome of ICD intervention (ineffective maximum-energy 
shocks followed by effective ATP burst) is compatible with inappropriate  ICD detection of a 
Supraventricular Tachycardia (SVT) as VT, the patient underwent Electrophysiological Study 
(EPS).  After the placement of two quadripolar electrodes in  right atrium and  right ventricle, an 
external defibrillation terminated atrial fibrillation and  also revealed the presence of Complete 
Heart Block (CHB) during sinus rhythm. Although the subsequent application of    pacing 
maneuvers did not produce any sustained tachycardia (Figure 3 A and B) we finally concluded 
that the clinical   episode was an appropriately detected VT, as the presence of CHB after 
cardioversion practically excludes the possibility of a prior  SVT episode with fast ventricular 
response. 
            Taking under consideration the absence of any detectable dysfunction of  the device 
(normal sensing and pacing function and, especially, acceptable defibrillation threshold) we 
suggested conservative treatment to the patient replacing verapamil with metoprolol plus 
amiodarone  and reprogramming the ICD therapy zones  in favor of ATP  versus shock therapy. 
Parameter: VT 330ms (Therapy: Rx1: 3 sequences Burst 5 Impulses R-S1 Interval 84%; Rx2: 3 
sequences Ramp 5 Impulses R-S1 Intervall 81%: Rx3: 3 sequences Burst 5 Impulses R-S1 
Interval 84%; 4-6 cardioversion 35J), FVT 270ms (Therapy: Rx1-3: 1 sequence Burst 5 
impulses R-S1 Intervall 84%; Rx 4-6: 3 times cardioversion 35J), VF 280ms (Therapy: 6 times 
DC-Shock 35J). SVT discrimination: Off. Stimulation parameter: VVIR 60 - 120 bpm. 
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Figure 1. A. First ineffective ATP burst after ICD detection of FVT episode. B. First (among five) ineffective 
maximum-energy shock. C. Application of a new APT burst terminates the tachycardia.
Figure 2. Successful testing of DC-shock-therapy after induction of VF by T-wave shock.
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Figure 3A. Complete Heart Block after external defibrillation for Atrial Fibrillation
(Ventricular pacing at 40 bpm).
Figure   3B.  Ventricular   stimulation   for   the   induction   of   VT   (RVOT   pacing,   three   extrasystoles).  
Atrial and ventricular stimulation before and after i.v. administration of isoproterenol didn't produce any sustained 
tachycardia.
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Discussion
            Ventricular tachycardia or fibrillation is usually the primary cause of sudden death  in 
patients with Hypertrophic Cardiomyopathy (HCM) and the only established therapy for the 
prevention of  sudden cardiac death in such patients  is the implantation of ICD5,6. Ventricular 
tachycardias   in patients with HCM may have focal origin (triggered activity,  abnormal 
automaticity   or  microreentry   circuit)   while  macroreentrant   mechanisms   are  increasingly 
recognized in these patients, related with the presence of scar areas (subendocardial or 
intramural scars, revealed by contrast-enhanced MRI)7 or apical aneurysm8.                          
            Previous reports have shown that ATP is  effective in terminating 80- 95%  of episodes 
of spontaneous VT with CL >300 ms1-3. Although VTs with shorter cycle length are usually 
treated with shocks  (ATP therapy has the risks of  tachycardia acceleration and syncope due to 
delay of definitive shock therapy) evidence support that  ATP can  safely terminate 40-80% of   
FVTs as well9,10, so as in current use of ICDs an ATP can precede the shock therapy, while the 
device is charging for shock delivery.                                                                               
               Ineffectiveness of shock therapy for the termination of detected episodes of VT or 
Ventricular Fibrillation (VF) in ICD recipients is  rare4,11,12. In these patients, false diagnosis of  
VT or Ventricular Fibrillation (VF) not responding to ATP or shock therapy is due to ICD 
dysfunction or inappropriate detection of an SVT episode as VT, while real incessant VT or VF  
is usually due to   acute myocardial ischemia and/or acute pump failure. Other possible 
explanations include antiarrhythmic drug toxicity (proarrhythmia), extreme electrolytic disorders 
and excessive alcohol   intake11,12. High defibrillation threshold has also been reported for  
patients with Brugada syndrome13.                                                                                   
            The efficacy of ICD therapy in terminating VT or VF  in patients with HCM has been 
documented, although the myocardial thickness and disarray, which are characteristic for this 
disease,   raise   theoretical   concerns   about   this5,6.   Additionally,   the   reported   incidence   of 
inappropriate shock therapy in patients with HCM is comparable with the total incidence among 
ICD recipients5,6.                                                                                                     
            In our case, our first aim was to examine the appropriateness of the ICD detection of VT  
in comparison to the more reasonable (according  to the response to therapy) explanation of  
inappropriate   detection   of   SVT.   Regarding   that   single-chamber   ICDs   perform   only 
intraventricular recordings  that cannot reassure the accurate differential diagnosis between VT 
and regular SVT, the diagnosis of VT in our  patient was finally confirmed during the EPS.     
            Although there was no detectable apical aneurysm in  echocardiographic study and left 
ventriculography,  the macroreentrant mechanism is still reasonable for the initiation and 
perpetuation of this VT episode, as the presence of subendocardial or intramural scar areas 
cannot be excluded (MRI was not performed). Moreover, Bundle Branch Reentry VT can be 
considered, as the patient has severe conduction system disease.  Regarding the possible focal 
origin of this VT episode, the spontaneous acceleration of  VT before ICD intervention  (warm-
up phenomenon) in addition to the ineffectiveness of shock therapy and the final response to 
ATP therapy make abnormal automaticity more reasonable mechanism, while triggered activity 
and microreentry cannot be excluded as well.                                                                         
               The failure of five consecutive   maximum-energy ICD shocks to terminate the VT 
episode can not be easily explained in the absence of ICD dysfunction, excessive myocardial 
disease, proarrhythmia or  electrolytic disorders. Additionally,  VT was not inducible during the 
EPS and the reproducibility of this unusual outcome of  ICD therapy could not be examined. In 
any case, different mechanisms are responsible for the perpetuation of a VF episode (either 
primary or due to degeneration of a VT episode) than VT.  In our case, this aspect as well as the 
acceptable defibrillation threshold test, make unreasonable any concern about no response to 
shock therapy of a possible VF episode in the future.                                       
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            According to the above, we applied a non-invasive therapeutic strategy for our patient, 
reforming the medical treatment and the ICD therapy zones. Radiofrequency ablation therapy 
has no significant role in patients with sustained VT due to HCM and is attempted  mainly in 
cases with macroreentrant VTs due to apical aneurysm8. Beta-blockers may increase the efficacy 
of ATP therapy, indicating a possible influence of autonomic tone in the maintenance of the 
VT10. The addition  of amiodarone to Beta-blocker might furthermore reduce the incidence of 
shock therapy in  patients with ICD, while the resultant  increase in the defibrillation threshold is 
small14,15. Among other antiarrhythmic drugs that may reduce the  incidence of ICD shocks, 
sotalol  is the most  reasonable  alternative.                                                                
            In conclusion, this is an unusual (to our knowledge the first reported) case of repeatedly 
ineffective maximum-energy  ICD  discharge for the termination of a FVT episode followed by 
effective ATP therapy,  in an ICD recipient with HCM, normal post-episode ICD control and 
acceptable defibrillation threshold. Concern about the efficacy of shock therapy in a possible 
future VF episode doesn't seem reasonable. Conservative therapy was suggested to the patient as 
there was no apparent role for any invasive therapeutic procedure.   Further investigation is 
needed   about   the   mechanisms   of   initiation,   perpetuation   and   termination   of   ventricular 
arrhythmias in patients with HCM.
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